EnSite to enter US trial for left atrial use:
This article was originally published in Clinica
Executive Summary
Endocardial Solutions is to begin a US clinical trial to assess its EnSite 3000 three-dimensional mapping system as a means of diagnosing arrhythmias, including atrial fibrillation, in the left atrium of the heart. The trial is expected to start in the second quarter of 2001 and will include up to eight institutions in the US and Canada, says the St Paul, Minnesota company. The product was cleared by the FDA for use in the right atrium in 1999. It is also available in Europe for right atrial and left ventricular use.